Oleptro

Oleptro is a brand name of trazodone, approved by the FDA in the following formulation(s):

OLEPTRO (trazodone hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: ANGELINI LLC
  
  Approval date: February 2, 2010
  
  Strength(s): 150MG ^[RLD], 300MG
  

Has a generic version of Oleptro been approved?

No. There is currently no therapeutically equivalent version of Oleptro available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oleptro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
  Patent 6,607,748
  Issued: August 19, 2003
  Inventor(s): Vincent; Lenaerts & Roland Herwig Friedrich; Beck & Elsie; Van Bogaert & Francois; Chouinard & Reiner; Höpcke & Cyril; Désévaux
  The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a controlled-release pharmaceutical formulation when compressed with pharmaceutical agent(s) in a tablet. Such cross-linked high amylose starch is prepared by (a) cross-linking and chemical modification of high amylose starch, (b) gelatinization, and (c) drying to obtain a powder of said controlled release excipient. In a preferred embodiment, such cross-linked high amylose starch is prepared in the following steps: (1) granular cross-linking and additional chemical modification (e.g., hydroxypropylation) of high-amylose starch; (2) thermal gelatinization of the starch from step (1); and (3) drying the starch from step (2) to yield a powder capable of being used as a controlled release excipient.
  
  Patent expiration dates:
  
  
  • June 29, 2020
    
    ✓ 
    Drug product
  
  



• 
  Trazodone composition for once a day administration
  Patent 7,829,120
  Issued: November 9, 2010
  Inventor(s): Gervais; Sonia & Smith; Damon & Rahmouni; Miloud & Contamin; Pauline & Ouzerourou; Rachid & Ma; My Linh & Ferrada; Angela & Soulhi; Fouzia
  Assignee(s): Labopharm Inc.
  Labopharm Europe Limited
  Labopharm (Barbados) Limited
  The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
  
  Patent expiration dates:
  
  
  • March 27, 2027
    
    ✓ 
    Patent use: METHOD OF TREATING DEPRESSION
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 2, 2013 - NEW DOSAGE FORM
  
  

See also...

• Oleptro Consumer Information (Drugs.com)
• Oleptro Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Oleptro Consumer Information (Cerner Multum)
• Oleptro Advanced Consumer Information (Micromedex)
• Trazodone Consumer Information (Drugs.com)
• Trazodone Consumer Information (Wolters Kluwer)
• Trazodone Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Trazodone Consumer Information (Cerner Multum)
• Trazodone Advanced Consumer Information (Micromedex)
• Trazodone Hydrochloride AHFS DI Monographs (ASHP)